Skip to main content
Cartilage Disorders Stem Cell Therapy
Orthopedic Treatment

Regenerative Approach for Cartilage Disorders

Medically reviewed by
Professor of Histology and Embryology · Medical Director, Center for Regenerative Medicine
Last reviewed
Next scheduled review

How we evaluate evidence · Conflict-of-interest disclosure · Editorial standards

Advanced MSC therapy to regenerate damaged cartilage, restore joint cushioning, and eliminate chronic joint pain without invasive surgery.

Can stem cell therapy help cartilage defects?

Mesenchymal stem cell therapy is not an approved treatment for adult cartilage defects. Cell-based procedures with regulatory approval exist for focal chondral defects — most notably autologous chondrocyte implantation and matrix-associated variants — used in selected patients. MSC-based injection alone has variable and inconsistent evidence. Established management — physiotherapy, activity modification, and surgical cartilage-repair techniques when indicated — remains the evidence-based path.

Key facts

MSC injection status
Not approved as a stand-alone cartilage-defect therapy
Approved cell procedures
ACI/MACI for selected focal chondral defects
Standard care
PT, activity modification, surgical cartilage repair when indicated

What we know

  • Autologous chondrocyte implantation is a regulator-approved cell therapy for selected focal cartilage defects.

What remains uncertain

  • Whether MSC injection provides added value over established cartilage-repair techniques in comparable patients.

Medically reviewed questions

No. There is no reliable evidence of adult cartilage regeneration from injection alone.

Those are regulator-approved procedures at specialised centres; ask about eligibility with an orthopaedic surgeon.

If your surgeon recommends it for a defined defect, surgery has evidence and should not be delayed for unproven options.

This summary is general medical information, not medical advice, and not a promise of benefit. Figures are quoted ranges, confirmed in writing after a medical review.

Medically reviewed by: Prof. Dr. Erdal Karaöz · Last updated: · Editorial and evidence policy

Evidence at a glance — Focal cartilage defects

A plain summary of what the published research does and does not show for this condition. It is written to the same standard whether the evidence is strong or weak.

Human studies available?
Yes — including controlled studies
Randomised trials?
A small number of randomised trials, plus comparative surgical series
Main outcomes studied
  • Defect fill on MRI
  • Pain and function
  • Return to activity
  • Reoperation rate
Long-term evidence
Limited
Regulatory approval for this indication
  • United States (FDA): No FDA-approved mesenchymal stem cell product for this indication. The FDA has issued consumer warnings about unapproved stem cell products.
  • European Union (EMA): No EMA-authorised mesenchymal stem cell medicine for this indication.
  • United Kingdom (MHRA): No MHRA-authorised mesenchymal stem cell medicine for this indication.
  • Türkiye (Ministry of Health): In Türkiye, cell therapies are delivered only inside Ministry of Health–licensed centres under the regenerative medicine / advanced therapy regulations, as clinical research or individual (exceptional) use — not as an approved routine treatment for this indication.
Role at our centre
Supportive consideration alongside standard care

What kind of evidence exists

  • Mechanism (laboratory): Documented
  • Animal / preclinical: Documented
  • Early human (phase 1/2, uncontrolled): Documented
  • Controlled human (randomised or sham-controlled): Documented
  • Regulatory approval: Not established

Sources

Source links open filtered searches of PubMed and ClinicalTrials.gov plus regulator and professional-society pages, so you can read the current evidence yourself rather than a selected extract.

Evidence last reviewed: Next scheduled review: Medical reviewer: Prof. Dr. Erdal KaraözRead our editorial and evidence policy

This summary is general information about the evidence base, not medical advice and not a promise of benefit. Whether any treatment is appropriate for you can only be decided after a medical review of your records.

Medically reviewed by Prof. Dr. Erdal Karaöz
Share:
Summarize with AI:
82%
Improvement Rate
100M+
Stem Cells
97%
Cell Viability
20+
Years Experience
Understanding the Condition

Understanding Cartilage Disorders

Cartilage disorders encompass a range of conditions where the smooth, protective tissue covering joint surfaces becomes damaged, thinned, or deteriorated. Unlike bone, cartilage has very limited natural healing capacity due to its lack of blood supply, making regeneration a significant clinical challenge.

Articular cartilage damage can result from acute trauma, repetitive stress, degenerative processes, or inflammatory conditions. Without intervention, cartilage loss progresses, leading to bone-on-bone contact, chronic pain, reduced mobility, and eventual need for joint replacement surgery.

Mesenchymal stem cell therapy represents a breakthrough approach to cartilage regeneration. MSCs can differentiate into chondrocytes, the specialized cells that produce and maintain cartilage matrix, while also creating an anti-inflammatory environment that protects remaining healthy cartilage from further degradation.

Cartilage disorder treatment
Conditions We Address

Types of Cartilage Disorders We Treat

Our regenerative protocols address multiple types of cartilage damage across various joints, with treatment plans tailored to each patient's specific condition.

Articular cartilage defects
Chondromalacia patellae
Osteochondral lesions
Meniscal cartilage damage
Talar dome lesions
Degenerative cartilage thinning
Post-traumatic cartilage injury
Early-stage osteoarthritis

Articular cartilage defects are focal areas of damage on the joint surface, often caused by sports injuries or trauma. MSC therapy promotes chondrocyte proliferation and new matrix formation at these sites.

Chondromalacia patellae involves softening and deterioration of the cartilage on the underside of the kneecap, causing anterior knee pain. Stem cells address both the structural damage and the inflammatory cascade driving cartilage breakdown.

Osteochondral lesions involve damage to both the cartilage and underlying bone, commonly affecting the knee, ankle, and elbow joints. Our protocols deliver MSCs to regenerate both tissue layers simultaneously.

Treatment Benefits

How Stem Cells Help Cartilage Disorders

Cartilage Regeneration

MSCs differentiate into chondrocytes and stimulate new cartilage matrix production in damaged joints.

Reduced Inflammation

Anti-inflammatory cytokines calm joint inflammation and protect remaining cartilage from further degradation.

Improved Mobility

Restored cartilage cushioning reduces bone-on-bone contact, improving joint range of motion and function.

Pain Relief

Addressing the root cause of cartilage loss provides lasting pain relief without repeated steroid injections.

Patient Experiences

Real outcomes from patients who chose regenerative medicine at StemCell Longevita Istanbul

"My orthopaedic surgeon in Munich said I'd need a new knee within a year. After regenerative medicine in Istanbul, that was two years ago and I still don't need it."

Before:Constant knee pain rated 8/10, unable to climb stairs, considering knee replacement surgery
After:Pain reduced to 2/10, walking 5 km daily, knee replacement postponed indefinitely
Hans K.
Germany·Knee Osteoarthritis

"I spent years managing pain instead of living. The treatment in Turkey gave me my active life back — something I didn't think was possible at my age."

Before:Chronic lower back pain for 5 years, limited mobility, dependent on daily painkillers
After:80% pain reduction, back to swimming and yoga, no longer needs daily medication
Maria T.
Italy·Degenerative Disc Disease
Care Process

Your Treatment Journey

Our image-guided approach ensures precise stem cell delivery to damaged cartilage for optimal regeneration results.

Step 01: Comprehensive Joint Assessment

MRI imaging, physical examination, and evaluation of cartilage damage severity and joint health.

Step 02: Personalized Protocol

Custom treatment plan based on the specific cartilage disorder, affected joints, and patient goals.

Step 03: MSC Preparation

High-quality mesenchymal stem cells prepared from Wharton's jelly with 97% viability guarantee.

Step 04: Targeted Delivery

Image-guided injection to deliver stem cells precisely to the areas of cartilage damage.

Step 05: Rehabilitation Support

Post-treatment physical therapy guidance and follow-up assessments to track cartilage regeneration.

Expert Care

Board-Certified Specialists

Our orthopedic specialists use advanced MRI and ultrasound imaging to precisely map cartilage damage and deliver stem cells to the exact areas requiring regeneration, maximizing treatment effectiveness.

FAQs

Frequently Asked Questions

Mesenchymal stem cells have demonstrated the ability to differentiate into chondrocytes — the cells responsible for producing cartilage matrix. When delivered to damaged joints, MSCs stimulate new cartilage tissue formation, produce growth factors that support existing cartilage health, and reduce the inflammatory environment that accelerates cartilage degradation.

We treat a range of cartilage disorders including articular cartilage defects, chondromalacia patellae, osteochondral lesions, meniscal cartilage damage, and cartilage thinning due to degenerative conditions. Each protocol is tailored to the specific type and location of cartilage damage.

Initial improvements in pain and mobility are typically noticed within 4-8 weeks. Cartilage regeneration is a gradual process, with MRI studies showing measurable cartilage thickness improvements at 3-6 months. Full therapeutic benefits continue to develop over 6-12 months as new cartilage matures.

For many patients, MSC therapy offers a minimally invasive alternative to surgical procedures like microfracture, mosaicplasty, or joint replacement. The treatment is performed via injection under image guidance, requires no hospitalization, and has significantly shorter recovery times compared to surgical interventions.

Our cartilage disorder treatment packages range from €6,950 to €14,950 depending on the severity and number of joints affected. All-inclusive packages include comprehensive evaluation, imaging, certified stem cells, treatment, hotel accommodation, VIP transfers, and follow-up care.

Restore Your Joint Cartilage

Stop cartilage degeneration and start regeneration. Discover how MSC therapy may restore your joint health without surgery.

Free PDF Guide

Download Our Free Cartilage Disorders Guide

Get our comprehensive patient guide with detailed treatment information, expected outcomes, and FAQs — all in one downloadable PDF.